LRRC41 Activators
LRRC41 activators comprise a group of compounds that influence various signaling pathways, resulting in the enhancement of LRRC41 activity. Forskolin, by directly stimulating adenylyl cyclase, induces a rise in cAMP levels, which are pivotal for the activation of PKA. PKA, in turn, phosphorylates a multitude of proteins that regulate the signaling pathways linked to LRRC41, thus facilitating its activation. Similarly, Epinephrine, upon binding to adrenergic receptors, also leads to an increased production of cAMP and subsequent PKA activation, which can enhance LRRC41 function. Rolipram and IBMX act as phosphodiesterase inhibitors, increasing intracellular cAMP and enabling PKA to phosphorylate proteins related to LRRC41 activity. Lithium's inhibition of GSK-3 and Okadaic Acid's inhibition of phosphatases such as PP1 and PP2A result in enhanced phosphorylation within the cellular signaling network, which could amplify LRRC41 activity.
Further, Anisomycin activates JNK, which phosphorylates proteins that may interact with LRRC41, enhancing its activity. SB 203580's inhibition of p38 MAPK and LY294002's inhibition of PI3K lead to alterations in their respective signaling pathways, which may, through various feedback loops or compensatory responses, result in the enhancement of LRRC41 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin directly activates adenylyl cyclase, thereby increasing levels of cAMP, which in turn leads to activation of PKA. PKA can phosphorylate various proteins that are involved in the signaling pathways that regulate LRRC41 activity, leading to its functional enhancement. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine binds to adrenergic receptors, which triggers a signaling cascade resulting in increased cAMP production. The elevated cAMP levels activate PKA, which then could phosphorylate substrates involved in the LRRC41-associated pathways, leading to its activation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram inhibits phosphodiesterase 4 (PDE4), leading to increased cAMP levels. This accumulation of cAMP activates PKA, which may target proteins associated with the same pathway as LRRC41, enhancing its activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, preventing cAMP breakdown, which leads to PKA activation. PKA can then enhance LRRC41 activity through phosphorylation of related signaling proteins. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium is known to inhibit glycogen synthase kinase-3 (GSK-3). Inhibition of GSK-3 can lead to activation of signaling pathways that are positively regulated by phosphorylation events, potentially enhancing the activity of LRRC41. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid inhibits protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels of proteins within signaling pathways that could be responsible for regulating LRRC41 activity. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a JNK activator, which can lead to the phosphorylation of proteins that may interact with or regulate LRRC41, thus enhancing its functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 inhibits p38 MAPK, which can lead to alterations in signaling cascades that indirectly result in the enhancement of LRRC41 activity due to compensatory mechanisms within the cell. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of PI3K, leading to alterations in the Akt signaling pathway. These changes can result in feedback mechanisms that may enhance the activity of LRRC41 through indirect effects on related signaling proteins. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A sc-24000B sc-24000C | 10 µg 100 µg 500 µg 1 mg | $160.00 $750.00 $1400.00 $3000.00 | 59 | |
Calyculin A, as an inhibitor of protein phosphatases, particularly PP1 and PP2A, causes an increase in protein phosphorylation within various signaling pathways, which could result in the enhancement of LRRC41 activity. | ||||||